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Summary We conducted a retrospective review of fatal bleomycin pulmonary toxicity in patients treated for germ cell tumours dunng
1991-95 at the Beatson Oncology Centre, Glasgow. Case notes of patients treated with bleomycin were reviewed with respect to cumulative
bleomycin dose, renal impairment, exposure to supplemental oxygen, thoracic radiotherapy and age. A total of 194 patients underwent
chemotherapy, of whom 180 received bleomycin-containing regimens. Five fatal cases of pulmonary toxicity were identified, an incidence of
2.8%. These cases were older than the remaining patients (P < 0.001), with a median age at diagnosis of 55 vs 33 years. The incidence of
fatal pulmonary toxicity increased with each decade of life above age 30. Renal function also differed between the two groups, with the worst
glomerular filtration rate recorded at the time of bleomycin administration for each patient, lower in the fatal group, median 69 vs 107 ml mirrn
(P < 0.001). There was no difference with respect to cumulative bleomycin dose or exposure to supplemental oxygen. For patients aged over
40 years, especially those with renal function in the lower range of normal, the risk of developing fatal toxicity may exceed 10%. The benefits
of bleomycin could be questioned for this age group.
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An anti-tumour antibiotic dexeloped from Streptomyces lverticul-
lus. bleomvcin has reported single-agent actix ity in up to 469% of
cases of germ cell tumours (GCTrs) (Haas et al. 1976). and has
been used in combination chemotherapy regimens for oxer 20
years. Possible toxicities include skin rashes. mucositis and hyper-
sensitivitv reactions. as xx-ell as bleomycmn pulmonary toxicitv
(BPT). In patients with seminoma or non-seminomatous tumours.
combinations that include bleomycin and cisplatin (together with
etoposide) yield response rates of over 90% in the majority of
cases. Bleomycin is clearly a valuable drur but. because of toxi-
city. particularly the nrsk of fatal BPT. its role in the treatment of
GCT has been questioned.
The reported incidence of non-fatal BPT is dependent on the
diagnostic criteria used. but appears to be 5-10%7. and fatal BPI
has been reported to occur in approximately 2% of treated cases
(Blum et al. 1973: Haas et al. 1976: Dalgleish et al 1984: White
and Stover. 1984: Comis. 1992). Early clinical data correlated an
increased BPT incidence with several nrisk factors'. These
included increasing cumulative bleomycin dose. the presence of
renal impairment. adjunctive thoracic radiotherapy. use of supple-
mental oxygen or age above 70. Experience in this unit has
prompted us to examine the relevance of age in particular detail as
we feel that an increasing, incidence of fatal BPT is evident at a
younger age than the quoted threshold of 70 years. Our concern
has been that the risk of fatal BPT might. in a subgroup of older
patients. outweigh the potential benefit ofbleomvcin as part ofthe
curative chemotherapy for GCT.
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METHODS
A retrospective case-sheet review Axas performed of all consecu-
tive cases of GCT treated with chemotherapy at the Beatson
Oncology Centre. Glasaow. during the 5-year period between
January 1991 and December 1995. Cases were identified by
review of the hospital admission database for this period as all
patients receiving bleomycmn-containing, chemotherapy for GCT
were treated as in-patients for the first few days ofeach cycle. The
identified cases were men treated for metastatic teratoma or semi-
noma. as well as those with high-risk stage I teratoma. Only those
patients who received chemotherapy were included in the rexiex
and those managed by surveillance alone were excluded from the
analysis.
The criteria used for diagnosis ofBPT x-ary between studies and
this is reflected by the xxide range in reported incidence oftoxicitv.
For the purposes of this retrospective study we have taken death
attributable to BPT as the key end point for analysis. as more
subtle presentations of BPT are open to interpretation and may be
rexersible. leaving the patient with no long-term sequelae.
Each case was reviewed with respect to the total bleomycin
dose received by the patient. age at diagnosis. treatment with
thoracic radiotherapy during or after chemotherapy and the lowest
glomerular filtration rate (GFR) of anv cycle at the time of treat-
ment xx-ith bleomycin. Measurement of the GFR had been
performed by varying techniques during the period under reviexx.
x-ith EDTA clearance. 24-h urine creatinine clearance or calcu-
lated creatinine clearance. Determination of GFR using one
of these methods had been carried out before each course of
chemotherapy. A further predisposing factor to the dexelopment
of BPT may be the use of supplemental inspired oxygen. espe-
ciallv at high concentrations. As xxe xxere not able to identify the
use of supplemental oxygen in anv patient before the dex elopment
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Table 1 Analysis of 180 germ cell turnour patients treated with bleonycin, 1991-96
Age No. of No. of bleomycin GFR range GFR mean Beomycin Bleomycin No. having Seminoma NSGCT HRSI GPM IPWI
(years) pabents deaths (ml min-') (ml min-') dose range (U) dose mean (U) surgery PPM
> 60 1 1 72 72 210 210 0 1 0 0 1 0
50-59 10 2 61-158 101 30-330 207 2 2 8 3 6 1
40-49 36 2 55-172 106 30-390 183 6 10 26 6 24 6
30-39 62 0 44-168 108 90-360 209 21 6 56 15 33 14
20-29 68 0 51-195 114 60-390 213 24 3 65 9 42 17
< 20 3 0 97-132 117 270-360 330 2 0 3 0 2 1
GFR. glomerular filtration rate: NSGCT. non-seminomatous germ cell tumour HRSI. high-risk stage l: GPM. good prognosis metastatic: IPM. intermediate
prognosis metastatic: PPM, poor prognosis metastatic.
of BPT other than in those undergoing surgers (usually for resec-
tion of residual tumour). we therefore used surgery as a surrogate
measure of supplemental oxygen exposure Ialthough this was
routineIx kept to low inspired oxygen concentrations).
The Mann-Whitnev U-test was used for the comparison of age.
GFR. cumulatisve bleom-cin dose and stage betu-een the BPT
fatalities and the rest. Pearson's chi-square test %was used for the
comparison of tumour histology and surgery. P-values for both
statistical tests were obtained from the package StatXact (C-tel.
1989.) which computes exact P-svalues.
RESULTS
During the study period. 194 patients had receis-ed chemotherapy
for treatment of GCT. of which 180 (93%7/) were treated with
bleom cmn-containing regimens. Treatment was either adjuvant or
for adsvanced disease. Of the 180 patients treated with bleomNcin-
containing, reaimens. 22 (12'%) had a histological diagnosis of
seminoma. The remaining 158 patients (88%7c) had non-seminoma-
tous GCT (NSGCT). which included those with combined
tumours as A-ell as those w-ith extra-testicular primary GCT. Table
1 shos s the characteristics ofall 180 patients revies ed. No patient
was treated s ith thoracic radiotherapy either during or after
completion ofchemotherapN.
Five fatal cases of BPT i ere identified in this cohort ofpatients
(Table 2). The diagnosis of BPT was made on clinical and radio-
logical grounds. and was confirmed in three cases by autopsy find-
ings. Consent for post-mortem examination in the remaining tso
cases was not obtained. The incidence offatal BPT for all patients
receivina bleomvcin-containing chemotherapy was 2.8%.
The fatal cases were compared with the remaining, 175 patients
with respect to established risk factors. Statistical analsysis. usinc
the Mann-Whitnev U-test. showed a significant difference in age
between the two groups (P < 0.001) Aith the fatal cases occurring
in older patients. median age 55 (range 43-67) years vs 33 (ranae
18-59) vears. The fatal cases also had significantly lower GFRs
(P < 0.001). median 69 (range 56-72) m mmin-' vs 107 (range
14-195) ml min-' at the time of bleomyrcin administration. No
significant difference was detectable between the two groups with
respect to cumulative bleomycin dose. surgery or sith tumour
histologv or stage.
The histories of the five fatal cases are presented below.
Case I
A 55 vear old wvas treated swith BEP (bleomycin 30 U sweeklv.
etoposide 165 mg m- day 1 + 2 + 3. cisplatin 50 mgrm day 1 + .
Table 2 Analysis of the five fatal cases of bleomycin pulmonary toxicity
Case Age Bleomycin dose GFR Surgery Histology Stage
(years) (units) (ml mirn')
1 55 330 61 No MTI GPM
2 44 120 56 No MTU PPM
3 43 270 69 No Chorio PPM
4 57 330 72 Yes Seminoma GPM
5 67 210 72 No Seminoma GPM
GFR. glomerular filtration rate: MTI. malignant teratoma intermediate: MTU.
malignant teratoma undifferentiated: GPM. good prognosis metastatic: PPM.
poor prognosis metastatic.
repeated every three w-eeks) chemotherapy for presumed
micrometastatic NSGCT. Orchidectomv had presviously shown
malignant teratoma intermediate w-ith areas of y olkW sac and
choriocarcinomatous differentiation.
Alphafetoprotein (AFP) and human chorionic gyonadotrophin
(HCG). although raised at diaanosis. had initially dropped before
increasina. AFP 1499 IU 1-1 (< 5). HCG 866 ILU 1-1 (<2). Staging
computerized tomography (CT) scan showed no evidence of
macroscopic metastases. He receis-ed four cycles of BEP
chemotherapy with a cumulatis e dose of 330 U ofbleomycin (the
final 30-U increment w~as w-ithheld because of the des elopment of
toxicityv). The tumour markers returned to normal by the beginning
of the second cycle. Near completion of chemotherapy he was
noted to hase deseloped basal crepitations on chest examination.
Chest radiograph (CXR) showed some patchy shadowing and CT
scan confirmed interstitial disease bibaso-posteriorlv. Pulmonars
function tests (PFTs) revealed a restrictis e lung defect and a
decreased carbon monoxide diffusion capacity (DLCO). 57%c of
that predicted. A clinical diagnosis of BPT was made and the
patient started on steroids with some initial benefit.
Ts o months later he developed a further increase in breathless-
ness. despite continuing steroids. CXR showed increased intrapul-
monars shadow-ing and PFT revealed a further decrease in DLCO
to 52%/ of that predicted. Despite increased steroids the dyspnoea
progressed. and serial CXR documented progressive fibrosis and
des elopment ofcavitating lesions. Progressive hypoxia desveloped
requiring increasing use of supplemental oxygen. Deterioration
continued and the patient died ofrespirators failure 10 weeks after
chemotherapy had finished. Autopsy showed diffuse alsveolar
damage and pulmonars fibrosis consistent with BPT: there was no
evidence oftumour.
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Case 11
A 44-year-old man presented A-ith 6 weeks of leg wk-eakness.
urinary hesitancv and constipation. A clinical diagnosis of cauda
equina syndrome %vas made on examination. CT scan showed
destruction of the sacrum by a large retroperitoneal mass 12.8 cm
in diameter. as w%-ell as tw-o liver metastases each measuring 5 cm.
The serum AFP Awas raised at 5163 IU 1-'. and biopsy of the
retroperitoneal mass showed GCT. He was treated initially w-ith
radiotherapy to the sacrum (30 Gy in ten fractions). To avoid prob-
lems with early myelosuppression. and because of the extent of
disease. he was treated with the BOP/VIP regimen (bleomycin.
xincristine. cisplatinum/etoposide. ifosfamide. cisplatinum: Lewis
et al. 1991). With the second cycle ofBOP chemotherapy. the AFP
lexel decreased to 43 IU 1-1. Two s-eeks after this cycle of
chemotherapy (cumulatixe bleomvcin dose 120 U). the patient
became increasingly dyspnoeic. CXR showed patchy consolida-
tion and he was started on empiric antibiotics for presumed
infection. Oxer the following days. the dyspnoea increased and
arterial oxygen saturations decreased. Examination revealed the
development of a left pleural rub and right-sided crepitations.
Bronchoscopy was negatix e for infection and CXR showxed
increasinc patchy consolidation. Because ofhyvpoxia he was trans-
ferred to the intensix e care unit for intubation and ventilation. The
hypoxia Awas progressix e and unresponsive to treatment.
Respiratorn arrest and death occurred 3 months after initial diag-
nosis of GCT. Autopsy showed a severe degree of pulmonary
fibrosis and extensixe GCIf with xiable tumour involxing the
Xertebral column. liver and retroperitoneum.
Case III
A 43-year-old man presented w-ith a short history of weight loss.
anorexia. nausea and loin pain. A rirht testicular mass was
palpable and confirmed by ultrasound scan. CXR rexealed
multiple pulmonary metastases. CT scans documented liver metas-
tases. para-aortic lymphadenopathy and a solitary left frontal cere-
bral lobe metastasis. Serum HCG was markedlx elex ated at above
2 million LU 1- He proceeded to excision of the cerebral metas-
tasis because of raised intracranial pressure and midline shift. A
4-cm haemorrhagic tumour wxas remoxed. and histologr showxed
choriocarcinoma. Right orchidectomy was also performned and
histology showed seminoma. Chemotherapy with cisplatin and
etoposide (but not bleomycin) wvas started the day after cran-
iotomy. At this time the patient developed dyspnoea thought to be
secondary to the pulmonary metastases. and respiratory function
progressixely deteriorated oxver the following days requiring
transfer to the intensive care unit for intubation and xentilation to
maintain arterial oxyaen saturations. CXR was unchanged from
the time of presentation. Respiratory failure was prolonged and
tracheostomy was performed. The patient slowly improx ed and. 3
weeks after onset. oxyvgen saturations of 95-98% xwere able to be
maintained wxith inspired oxygen. The patient A-as then able to be
weaned from the supplemental oxygen wxith arterial saturations
remaininc above 90%7. During this period. chemotherapy xxas
continued with cisplatin. methotrexate and vincristine. The HCG
level decreased from 2 350 000 IU 1-1 at the start ofchemotherapy
to 18 344 L 1-' oxer this time. Serial CXR showed a slirht
decrease in the size of the metastases. but no other changes. He
Table 3 Summary of trials assessing role of bleomycin in germ cell tumours
Study Patients Regimen Patient Cherotherapy No evidence of Disease-ree Relapse Overall Bleomycin
numbers disease after survival rate survival toxicity
che ,mm-apy
± surgery
Loehrer et al GCT. PVP16 85 Cisplatin 20 mg m-2 days 1-5 88% 690% 230o 86°0
(1995) mirimod vs Etoposide 100mg m-2 days 1-5
disease PVP16B 86 ±bleomycin 30 U week-' 94%o 86% 10°o 95%O Nil reported
3weeklyx3 P=0.2 P=0.01 P=0.01
Levi et al GCT. PV 108 Cisplatin 100mg m-2day 1 89%: 710o 70o
(1993) good vs Vinblastine 6 mg m-2days 1+2 NS
prognosis PVB 112 rbleomycin 30 U weekly 94%o 840o 50o Two deaths
(CR+ two cycies, median 4) P= 0.29
De Wrtetal NSGCT. EP 195 Cisplatin 20 mg m-2 days 1-5 87% 90°o 4°o
(1997) good vs Etoposide 120 mg nr2 days 1.3.5 NS
prognosis BEP 200 ±bleomycin 30 U weekly 95% 940o 40o Two deaths
3 weekdy x 4 P= 0.0075
Bosl et al GCT. EP 82 Cisplabtin 20 mg m-2 days 1-5 93%o 12°o
(1988) good Etoposide 100mg m-2 days 1-5
prognosis 3 weekly x 4 NS
vs
VAB-6 82 Vinblastine 4mg m-2 day 1 960o 1100 No deaths. 13
Cyclophos 600 mg m-2 day 1 P= NS patients
Dactinomycin 1 mg m-2 day 1 stopped bleomycin
Bleomycin 30 U day 1 because of
Bleomycin 20 U m-2 days 1-3 DLCO
Cisplatin 120mg rn 2 day 4
4 weekly x 3
NS. not sigificant
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was then started on BEP chemotherapy as he was no longer
requiring supplemental oxygen and received three cycles of treat-
ment. followed by two cycles ofEP, over the following 4 months.
A total dose of 270 U of bleomycin was given. The serum HCG
continued to decrease until it reached aplateau of40 IU 1-'.during
the second cycle of EP chemotherapy. Coincident with this cycle
of chemotherapy, he developed breathlessness and a cough with
mild haemoptysis. Basal crepitations were present on examination
and CXR showed decreased lung volume and bilateral fibrosis
consistent with bleomycin toxicity. The extensive pulmonary
metastases, although still present. had decreased in size. He was
started on dexamethasone 16 mg day-' and his dyspnoea
improved. The steroids were then weaned over a 2-week period.
Furtherchemotherapy with cisplatin, methotrexate and vincristine
was given as the HCG level had not normalized. One month later
his condition deteriorated and steroids were reintrduced. Arterial
oxygen saturations continued to decrease and supplemental
oxygen was required. There was further deterioration and the
patient died ofrespiratory failure 2 months after the clinical diag-
nosis ofBPT was made. Consent for an autopsy was not obtained.
Caw IV
A 57-year-old man was investigated because of an 8-month
history of backache and weight loss. A large retroperitoneal mass
was found on CT scan and investigational laparotomy was
performed. This showedhaemorrhagic tumourextending from the
epigastrium to the aortic bifurcation. The mass was thought inop-
erable and a biopsy was taken. Histology showed carcinoma with
areas suggestive of seminoma. Both HCG (30 IU 1-') and lactate
dehydrogenase [LDH; 2000 IU 1-1 (< 180)] were raised. AFP was
normal. Further investigation revealed an abnormality of the left
testis on ultrasound scan. He was treated with four cycles of BEP
chemotherapy,receiving a total of330 U ofbleomycin (bleomycin
on day 15 cycle 1 was withheld because of thrombocytopenia).
Tumour markers normalized after the first cycle of treatment. CT
scan documented a decrease in the size of the retroperitoneal
mass. with a maximum diameter of 8 cm at the completion of
chemotherapy. Repeat testicular ultasound showed patches of
calcification in the previously abnornal area. Because ofthe large
size of the residual mass and lack of definitive histology, he
proceeded to resection of the mass and orchidectomy (2 months
after the lastbleomycin dose). This was a prolonged procedure of
9 h requiring both laparotomy and thoraco-abdominal incision.
There was an estimated 9.51 blood loss during the procedure, and
two chest drains were left in situ at the conclusion oftheoperation.
He received inspired oxygen concentrations of 3440% during
surgery and maintained arterial oxygen saturations above 90%. He
was transferred to the intensive care unit with respiratory and renal
compromise. CXR showed extensive alveolar shadowing of both
lungs. Pulmonary artery catheterization showed high pressures
consistent with fluid overload. He was treated with dopamine and
frusemide infusion. renal dialysis and high-dose corticosteroids.
Forty per cent inspired oxygen was required to maintain arterial
oxygen saturation at 85-90%. Some days after admission to the
intensive care unit. treatment was complicated by gastrointestinal
haemorrhage, and two duodenal ulcers were found on endoscopy.
The haemorrhage stabilized with fluid and blood support.
Pulmonary function continued to deteriorate throughout this time.
and the patient died from respiratory failure 3 weeks after surgery.
Autopsy showed diffuse interstitial pulmonary fibrosis and hyper-
plasia of type II pneumocytes consistent with BPT. Three large
duodenal ulcers were also identified. Histology of the surgical
resection showed necrotic tissue only. with no evidence ofresidual
tumour.
Case V
A 67-year-old was treated with radiotherapy to the para-aortic
lymph nodes (30 Gy in 15 fractions). for a stage HB seminoma
documented by orchidectomy and CT scan. One year later he
presented with chest discomfort and cough. CXR showed a right
hydropneumothorax. and a chest drain was inserted. LDH was
raised at 618, although AFP and HCG were within normal limits.
CT scan revealed a large posterior chest mass, with multiple lung
nodules and mediastinal lymphadenopathy. Pleural biopsies
showed recurrent seminoma. He was treated with BEP
chemotherapy, receiving a total dose of 210 U of bleomycin
(bleomycin was withheld cycle 1 days 8 and 15 because of
hospital admission with neutropenic fever). Chemotherapy was
complicated by grade Ill mucositis and prolonged neutropenia
during the first cycle, for which he was treated with granulocyte
colony-stimulating factor (GCSF) and empiric antibiotics. Repeat
CT scan of the chest at the completion of chemotherapy showed
residual thickening in the previous area of abnornality. Two
months aftercompletion ofchemotherapy he returned with breath-
lessness and a dry cough. Examination revealed crepitations at the
leftlung base. and CXR showedpatchy shadowing in this area. He
was treated empirically with antibiotics, although afebrile. but his
condition worsened. He became markedly hypoxic and was started
on supplemental oxygen and corticosteroids. There was a transient
improvement before continued deterioration. Repeat CXR showed
extensive bilateral pulmonary shadowing consistent with BPT.
Bronchoscopy, although planned. was not carried out because
of worsening clinical state. The patient had a respiratory arrest
and died. Permission for autopsy was denied. The diagnosis of
BPT was made on clinical history. examination and radiological
findings.
DISCUSSION
The first reports of BPT described an incidence of 5% among
patients receiving total cumulative doses of bleomycin below
450 U (Blum etal, 1973). Forcumulative doses greaterthan 550 U
the incidence ofBPT increased to 17%, with an intermediate inci-
dence of 13% for doses between 450 and 550 U. Fatal BPT
occurred in less than 1% ofpatients at the lowerdose but increased
to above 10% for those who received over 550 U of bleomycin.
The correlation ofdose with toxicity was confirmed by Haas et al
(1976), who found that for patients experiencing BPT the mean
cumulative dose of bleomycin administered was significandly
greaterthan that receivedby patients not developing toxicity. Fatal
BPT can occur below the 450 U threshold. and the onset of BPT
has beenreported atcumulative doses lowerthan 100 U (Wilson et
al, 1982; McLeod et al, 1987). Few patients receive cumulative
doses above 360 U, and our present practice is to implement a
ceiling of 270 U. The majority of our patients had been entered
into current EORTC and/or MRC randomized trials over the study
period. Within these trials.and forthose patients not treated as part
of a study protocol,bleomycin was given at a dose of 30 U either
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as a 1-h intravenous infusion or as an intramuscular injection (for
patients receiving outpatient treatment). In no case was bleomycin
given as an intravenous bolus injection. The majority ofprotocols
stipulated weekly doses of bleomycin (a total of 90 U per 3-week
cycle), with a total of four cycles of treatment (i.e. a maximum of
360 U ofbleomycin). The mean cumulative dose ofbleomycin, in
our patients, was lower than we expected from our current prac-
tice. but 43 ofthe patients reviewed had been treated on studies in
the early 1990s that prescribed a single dose of30 U ofbleomycin
with each cycle of chemotherapy, with a protocol ceiling dose of
120 U.
BPT has been reported in patients with renal impairnent at low
cumulative bleomycin doses (Bennett et al, 1980; Dalgleish et al,
1984: McLeod et al. 1987; Blayney et al, 1993). The terminal half-
life of bleomycin is 2-4 h. and 70% of the administered dose is
excreted in the urine within the first 24 h. The half-life can be
greatly increased in the presence of renal impairment, with an
exponential rise in the half-life as the creatinine clearance
decreases below 35 ml min-'. A bleomycin half-life of 21 h has
been reported in a patient with a creatinine clearance of only
10.7 ml min-' (Crooke et al, 1977). Dose reduction is suggested for
patients with creatinine clearances below 35 ml min-'; however,
the development of BPT has been noted in cases with lesser
degrees of renal impairment in the absence of other risk factors
(Dalgleish et al, 1984). The GFR of our fatal group was signifi-
cantly lower than that of the non-fatal group, although there were
comparable levels of renal impairment within the non-fatal group.
No patient had a dose reduction on the basis of their GFR, as the
values were within acceptable treatment limits.
Goldiner et al (1978) reported five fatal cases ofBPT in patients
post surgery. The onset of BPT after surgery was rapid, although
the most recent administration of bleomycin in these patients had
been 6-12 months previously. Goldiner et al postulated that the
onset of BPIT in these patients was related to the use of high
inspired oxygen concentrations of 34-40% during surgery, and
extensive fluid replacement (blood loss was often 10-15 units)
during the 6- to 8-h operation. When the inspired oxygen concen-
tration was kept between 22% and 24%. and fluid status was
closely monitored with Swan-Ganz catheterization during opera-
tion. there were no further cases of BPT in patients undergoing
similar procedures. The potentiation of BPT by high inspired
oxygen concentration has been supported by animal studies (Tryka
et al. 1984). In this review we have used surgery during or after
chemotherapy as a surrogate measure ofexposure to supplemental
inspired oxygen before the development of BPT. as it was only
during operations that the patients were exposed to supplemental
oxygen according to clinical circumstances, although attempts
were generally made to keep it low. There was no difference
between the two groups in the frequency ofoperations performed.
and therefore there was no discernible effect of supplemental
oxygen on the frequency offatal BPT.
The fifth fatal case received teatment with GCSF because of
grade HI prolonged neutropenia complicated by fever, during one
cycle of chemotherapy. The possibility of synergy between
bleomycin and GCSF in the aetiology of BPT has been raised
(Matthews, 1993; Dirix et al, 1994) but has been refuted. In a large
MRCIEORTC trial in which 263 patients receiving BEP or
BOP/VIP chemotherapy for testicular teratoma were randomized
either to receive GCSF or not, there was no evidence ofan increase
inBPTinthe GCSFarm(Fossaet al, 1995).
All five fatal cases reviewed were over the age of40. although
only 47 ofthe 180 patients treated with bleomycin were in this age
group. Blum et al (1973) reported a BPT incidence of 2-6% for
each decade oflife, which increased dramatically to 15% for those
patients over 70 years (interestingly six of the seven deaths
reported in his paper occurred in patients over age 40). The risk of
developing fatal pulmonary toxicity is related to age, but we are
concerned that the threshold of accelerating risk is below that
traditionally quoted of 70 years (Blum et al. 1973: Haas et al.
1976). and that this threshold may be apparent in the fifth decade
oflife. The role ofbleomycin, as part ofcurative treatment, in this
subgroup ofpatients needs to be considered-
Our current standard therapy for good-prognosis GCT is four
cycles ofBEPchemotherapy. Einhom et al (1989) reported that for
the treatment of favourable prognosis GCT, three cycles of BEP
chemotherapy were as effective as four. Decreasing the total
administered dose of bleomycin (as well as that of cisplatin and
etoposide) by omitting the fourthcycle did notcompromise patient
outcome, and was also associated with less treatmenttoxicity. This
observation is cufrently being tested in a large prospective
randomized MRC/EORTC trial (three vs four courses of BEP
chemotherapy), although in this trial bleomycin is omitted from
the fourth course of BEP (effectively a course of cisplatin and
etoposide chemotherapy) in order to ensure an equal total dose of
bleomycin (270 U) in both teatment arms.
A review of the literature indicates that four randomized trials
have been performed assessing whether bleomycin could be with-
held from standard regimens to lessen toxicity without compro-
mising clinical response. The weight of evidence from these
studies (Table 3) suggests that disease-free survival (DFS) of
patients with good-prognosis disease decreases if bleomycin is
omitted from these chemotherapy regimens. This is apparent with
the individual trials showing eitherdecreased initial response oran
increased relapse rate if bleomycin is not used. The ECOG trial
(Loehrer et al, 1995). which employed only three cycles of
chemotherapy, showed the largest increase in relapse rate as a
result ofomitting bleomycin, and the trial was closed as a result of
an interim analysis. In many centres this has led to the adoption of
a policy of treating with three cycles of BEP as routine, or with
four cycles of EP if bleomycin is contra-indicated. The EORTC
trial (De Wit et al, 1997). the largest individual trial, shows a
statistically significant decrease from 95% to 87% in attaining
a disease-free state is bleomycin is withheld from primary
chemotherapy, but only a4% difference in DFS. and no significant
difference in the overall survival of treated patients. This trend is
supported by the other studies, although does not reach statistical
significance, perhaps because of their smaller size. Most of the
trials report similarrelapse rates between their two treatment arms.
The trial from the Memorial Sloan-Kettering Cancer Centre (Bosl
et al. 1988) shows no significant difference in outcome between
the two treatment arms. but the combinations being compared
differed in other respects as well as the omission of bleomycin.
hence the results are not directly comparable with the other trials.
Three ofthese four trials included both patients with seminoma
or NSGCT in their analyses. although the numbers treated for
seminoma were small. Previous studies have found cisplatin and
etoposide chemotherapy to be highly effective treatment for
advanced seminoma with a DFS of about 90% (Mencel et al.
1994). but the benefit ofadding bleomycin to cisplatin and etopo-
side for this subgroup ofGCT has not been studied. The peak age
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incidence of seminoma is substantially different from that of
NSGCT. 35-39 years vs 25-29 years respectively (Forman and
Moller. 1994). and therefore is more prevalent among the older
GCT patients. i.e. the subgroup of patients that we feel are at
greater risk ofdeveloping fatal BPT.
In our view. for that group of patients with GCT over 40 years
of age. particularly those with a GFR at the lower end of the
normal range. it is preferable to accept the possibility of a reduc-
tion in DFS by perhaps 4% in order to avoid a risk of fatal BPT
that may exceed 10%. We have therefore discontinued the routine
use of bleomycin in these patients. with good prognosis disease.
for whom our standard regimen comprises fourcycles oftreatment
with cisplatin and etoposide.
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